LLY vs PROF
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
LLY shows neutral fundamentals based on deterministic rules. Financial strength is weak (F-Score 3/9). Mixed signals with both opportunities and risks present.
The deterministic health profile is critical, highlighted by a Piotroski F-Score of 1/9, indicating severe fundamental weakness. While the company exhibits strong top-line momentum with 43.10% YoY revenue growth and a healthy gross margin of 70.77%, this is completely offset by a catastrophic profit margin of -264.44%. The company is essentially a high-burn growth play with a very expensive valuation (P/S of 14.99) and a long history of negative earnings. Only the exceptionally high current ratio (12.53) and low debt provide a temporary safety net against insolvency.
Compare Another Pair
Related Comparisons
LLY vs PROF: Head-to-Head Comparison
This page compares Eli Lilly and Company (LLY) and Profound Medical Corp. (PROF) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.